CompletedNCT01003379
TC-5619 added to treatment for thinking difficulties in schizophrenia
About this title
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
Read the official source — NCT01003379This study evaluated the safety and effectiveness of TC-5619 for people with schizophrenia.
Medication studyAges 18–60India + United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of TC-5619 for people with schizophrenia.
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- National City and 15 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateOctober 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 184
- Sponsor
- Targacept Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, India
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01003379
- Official title
Show the full official title
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
Get this study by email
Recruitment & locations
CompletedNational City, United States · Torrance, United States · Atlanta, United States
11 more locations
- Wichita, United States
- Cedarhurst, United States
- New York, United States
- Austin, United States
- Guntur, India
- Hyderabaad, India
- Visakhapatnam, India
- Mangalore, India
- Mysore, India
- Kanpur, India
- Lucknow, India
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of TC-5619 for people with schizophrenia.
Who is behind this study?
The study sponsor is Targacept Inc.
Did this study involve medication?
Yes. The study involved medication, including TC-5619 and Placebo.
Who was this study for?
Listed age limits: 18 years to 60 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia